Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
0.6480
+0.0718 (12.46%)
At close: Nov 17, 2026, 4:00 PM EST
0.6762
+0.0282 (4.35%)
After-hours: Nov 17, 2026, 6:05 PM EST

Company Description

Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally.

It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.

The company is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd
Tiziana Life Sciences logo
CountryUnited Kingdom
Founded2013
IPO DateMar 24, 2000
IndustryBiotechnology
SectorHealthcare
Employees10
CEOIvor Elrifi

Contact Details

Address:
14/15 Conduit Street
London, W1S 2XJ
United Kingdom
Phone44 20 7495 2379
Websitetizianalifesciences.com

Stock Details

Ticker SymbolTLSA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001723069
CUSIP NumberG88912103
ISIN NumberBMG889121031
SIC Code2834

Key Executives

NamePosition
Dr. Ivor R. Elrifi Ph.D.Chief Executive Officer and Executive Director
Gabriele Marco Antonio Cerrone M.B.A.Founder and Executive Chairman
Keeren ShahChief Operating Officer and Chief Financial Officer
William Edward Tente M.S.Chief Regulatory Officer
Dr. Richard K. Kim M.D.Chief Medical Officer
Dr. Napoleone Ferrara M.D.Member of Scientific Advisory Board

Latest SEC Filings

DateTypeTitle
Nov 16, 2026SCHEDULE 13G/AFiling
Nov 12, 20266-KReport of foreign issuer
Nov 9, 20266-KReport of foreign issuer
Nov 9, 20266-KReport of foreign issuer
Nov 5, 20266-KReport of foreign issuer
Nov 2, 20266-K/AFiling
Nov 2, 20266-KReport of foreign issuer
Oct 21, 20266-KReport of foreign issuer
Oct 16, 20266-KReport of foreign issuer
Oct 16, 20266-KReport of foreign issuer